RecruitingPhase 2NCT07065630

Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

A Phase II Study of Volrustomig, Paclitaxel, and Carboplatin Followed by Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer


Sponsor

University of Chicago

Enrollment

38 participants

Start Date

Oct 7, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and neck squamous cell carcinoma .


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new treatment approach for people with advanced head and neck cancer that has NOT been caused by HPV (human papillomavirus). The goal is to adjust treatment based on how well the cancer responds early on, using a combination of immunotherapy drugs. **You may be eligible if...** - You have been diagnosed with advanced (stage IV) squamous cell cancer of the mouth, throat, voice box, sinuses, or related areas - Your cancer has tested negative for HPV (and negative for EBV if in the nasopharynx) - You have NOT previously received radiation, chemotherapy, or immunotherapy for head and neck cancer - You are 18 or older and are in reasonably good physical condition (able to care for yourself) - Your heart, liver, kidneys, and blood counts are in acceptable range **You may NOT be eligible if...** - Your cancer has spread to distant parts of the body (metastatic) - You have had major surgery to remove your head and neck tumor - You have a serious autoimmune disease (like lupus or Crohn's disease) - You have uncontrolled heart problems, active hepatitis B/C, HIV, or tuberculosis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVolrustomig

500mg or 750mg (cycles 1-2) and 250mg thereafter IV day 1.

DRUGCarboplatin

100mg/m2 IV day 1 and day 8.

DRUGPaclitaxel

AUC 5 IV day 1


Locations(1)

The University of Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07065630


Related Trials